| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 77 | 14.2x | 17.6x | Top tier | |
Growth | 81 | 17.1% | 7.1% | Top tier | |
Quality | 64 | 14.6% | 4.5% | Around median | |
Safety | 47 | 2.9x | 2.6x | Around median | |
Capital Return | 22 | 1.38% | 2.15% | Bottom tier | |
Momentum | 22 | -6.6% | 2.3% | Bottom tier | |
Sentiment | 69 | 4 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Phibro Animal Health Corporation operates in animal health, mineral nutrition, and performance products, generating revenue from medicated feed additives, vaccines, nutritional specialties, mineral premixes, copper-based products, and ingredients for industrial and personal care applications. The Animal Health segment is the primary driver; its portfolio includes legacy products and the medicated feed additives portfolio acquired from Zoetis, alongside solutions such as Bovatec, Deccox, Aureomycin, and the Start Strong packages targeting livestock markets.
In Q4 of fiscal year 2026 ended June 30, 2026, revenue reached $396.7 million, up 5% year over year, gross profit was $134.4 million with a gross margin of approximately 33.9%, and net income was $21.7 million. The company generated adjusted earnings of $0.85 per share, compared with estimates of $0.72 and $0.57 in the comparable period. Animal Health accounted for approximately 75% of quarterly sales, with revenue of $297.6 million, compared with $77 million for Mineral Nutrition and $22.2 million for Performance Products.
In fiscal year 2026, Phibro reported record revenue of $1.518 billion, up 17%, gross profit of $512.5 million with a margin of approximately 33.8%, net income of $99.7 million, and earnings per share of $2.43. Animal Health revenue increased 21% to $1.162 billion, Mineral Nutrition increased 11% to $282.3 million, while Performance Products declined 8% to $73.5 million. Adjusted earnings before interest, taxes, depreciation, and amortization also increased 39% to $255 million, driven by the integration of the Zoetis portfolio, an improved product mix, and the Phibro Forward initiative.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” but the average price target of $28 is below the lower end of the 52-week range of $28.25 and significantly below its high of $60.08. The wide range of targets between $17 and $49 also reveals substantial divergence in assessing the impact of slower fiscal year 2027 growth, virginiamycin risks, and financial leverage, and the available data do not include a valid price-to-earnings ratio that can be used to confirm whether the valuation is inexpensive or elevated.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Revenue reached $396.7 million in Q4 of fiscal year 2026, up 5% year over year, and net income reached $21.7 million. Adjusted earnings per share were $0.85 versus expectations of $0.72, while adjusted earnings before interest, taxes, depreciation, and amortization increased 29%. The improvement came from demand growth, a better product mix, lower input costs, and the impact of a one-time tariff recovery, offset by pressure from higher employee-related expenses.
The Animal Health segment generated sales of $1.162 billion in fiscal year 2026, representing approximately 77% of the company's $1.518 billion in revenue. Segment sales grew 21%, and its adjusted earnings before interest, taxes, depreciation, and amortization increased 37% to $303.6 million. Its drivers include medicated feed additives, vaccines, nutritional specialties, and products such as Bovatec, Deccox, and Aureomycin within the Start Strong package.
The company expects revenue between $1.55 and $1.60 billion in fiscal year 2027, representing growth of between 2% and 5%. It expects adjusted earnings before interest, taxes, depreciation, and amortization between $258 and $268 million, and adjusted earnings per share between $3.41 and $3.59. The guidance assumes a very minimal contribution from virginiamycin in Brazil, and management also expects negative operating earnings growth during Q1 of fiscal year 2027 followed by a return to positive growth during the remainder of the year.
virginiamycin sales in Brazil reached approximately $27 million in fiscal year 2026, but the status of its therapeutic uses is subject to regulatory review. Management based fiscal year 2027 guidance on the assumption of no sales after Q1 and a very minimal annual contribution. Because the product has a high margin, its absence puts greater pressure on earnings and margins than its direct impact on revenue, while regulatory approval would be a positive factor not included in the outlook.
Total debt reached $738 million and net debt reached $656 million at the end of fiscal year 2026, with gross leverage of 2.9 times and net leverage of 2.6 times relative to $255 million in adjusted earnings before interest, taxes, depreciation, and amortization. Free cash flow did not exceed $10 million, as operating cash flow reached $69 million and capital expenditures reached $59 million. The inventory build of $86.3 million was the largest pressure factor, and management expects inventory build in fiscal year 2027 to be limited to between $25 and $30 million related to the Chicago Heights transition.
Phibro expects a limited positive impact on adjusted earnings before interest, taxes, depreciation, and amortization in fiscal year 2027, followed by an annual benefit of between $15 and $20 million in fiscal year 2028 and beyond. One-time cash costs are estimated at approximately $10 million, in addition to approximately $10 million in capital expenditures to transfer some production to internal sites. The company has not yet determined the value of the non-cash asset write-down or the site's final value, and it will also build additional inventory during the transition period to maintain customer service.
